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Abstract
Background/Aims: Estrogen-mediated cholestasis is an important clinical entity, but its molecular pathophysiology is still not fully
understood. Impaired sodium-dependent uptake of bile acids has been associated with diminished expression of a basolateral Na+/bile acid
cotransporter (Ntcp), whereas sodium-independent uptake is maintained despite a down-regulation of the organic anion transporter Oatp1.
Thus, expression of the two other rat Oatps (Oatps2 and -4) was determined in estrogen-induced cholestasis. In addition, known
transactivators of Oatp2 and Ntcp were studied to further characterize transcriptional regulation of these transporter genes. Methods: Hepatic
protein and mRNA expression of various Oatps (1, 2, 4) in comparison to Ntcp were analyzed after 0.5, 1, 3 and 5 days of ethinylestradiol
(EE) treatment (5 mg/kg) in rats. Binding activities of Oatp2 and Ntcp transactivators were assessed by electrophoretic mobility shift assays.
Results: All basolateral Oatps (1, 2 and 4) were specifically down-regulated at the protein level by 30–40% of controls, but less pronounced
than Ntcp (minus 70–80%). In contrast to unaltered Oatp4 mRNA levels, Oatp1 and Oatp2 mRNAs were reduced to various extents (minus
40–90% of controls). Binding activity of known transactivators of Ntcp and Oatp2 such as hepatocyte nuclear factor 1 (HNF1), CAAT
enhancer binding protein a (C/EBPa) and pregnane X receptor (PXR) were also diminished during the time of cholestasis. Conclusions:
Estrogen-induced cholestasis results in a down-regulation of all basolateral organic anion transporters. The moderate decline in expression of
Oatp1, -2 and -4 may explain the unchanged sodium-independent transport of bile acids due to overlapping substrate specificity. Reduction in
transporter gene expression seems to be mediated by a diminished nuclear binding activity of transactivators such as HNF1, C/EBP and PXR
by estrogens.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Estrogens are well known to cause reversible intrahepatic
cholestasis in humans and rodents. Intrahepatic cholestasis
occurs in susceptible women during pregnancy, administra-
tion of oral contraceptives and postmenopausal hormone
replacement therapy [1]. Since its first description in 1954
[2] cholestasis of pregnancy has been of major clinical and
experimental interest for almost five decades. Despite differ-
ences in estrogen levels between the rat model and pregnant
women, 17a-ethinylestradiol (EE) treatment of rats has been
widely accepted as one animal model of the human disease
entity [3]. However, its molecular pathomechanisms are
multifactorial and still largely unknown.
Physiologically, organic anions are taken up from portal
blood by a sodium-dependent taurocholate cotransporter
(rat: Ntcp, Slc10a1; human: NTCP, SLC10A1) and several
members of a growing family of sodium-independent
organic anion transporters (Oatps). After rapid transhepatic
transport to the canalicular membrane, organic anions are
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secreted into the bile by two ATP-dependent export pumps,
the bile salt exporting pump (rat: Bsep, Abcb11; human:
BSEP, ABCB11) and the multidrug-resistance protein 2 (rat:
Mrp 2, Abcc2; human: MRP2, ABCC2) [4].
Estrogens induce cholestasis by reducing both bile salt-
dependent (BSDF) and bile salt independent bile flow
(BSIF) [1]. Several studies indicate that early generalized
abnormalities of the sinusoidal membrane fluidity, Na(+)–
K(+)–ATPase activity and reduced Ntcp, Oatp1 and
Mrp2 expression contribute to EE-induced cholestasis
[3,5,6]. Reduction in BSIF parallels the impairment in
glutathione and bicarbonate excretion and might be a
correlate of decreased Mrp2 protein expression [7,8].
However, decreased canalicular ATP-dependent taurocho-
late transport in hepatocyte canalicular membrane prepa-
rations [5] is thought to result rather from trans-inhibition
of Bsep following Mrp2-dependent transport of EE into
the canaliculus than from changes in gene expression [9–
12].
At the basolateral membrane, uptake of bile salts and
certain organic anions such as sulfobromophthalein is
markedly impaired under these conditions [5,13,14] and
might result, at least in part, from the down-regulation of
Ntcp and Oatp1 expression. However, differential down-
regulation of the three members of the Oatp family
expressed in the liver has been shown during extrahepatic
cholestasis [15]. Oatp1 (Slc21a1) decreases by 90% 7 days
after ligation of the common bile duct whereas Oatp2
(Slc21a5) and Oatp4 (Slc21a10) expression is unaffected
[15]. This differential down-regulation may affect the excre-
tion of important endogenous and xenobiotic substrates.
Oatp1 (Slc21a1), Oatp2 (Slc21a5) and Oatp4 (Slc21a10)
[16–19] are involved in the absorption and elimination of a
wide variety of structurally unrelated amphipathic organic
compounds from sinusoidal blood and represent multispe-
cific transport systems with distinct but partially overlap-
ping transport specificities [20–23].
Despite the long interest in estrogen-induced cholestasis,
the mechanisms of altered sinusoidal uptake in estrogen-
associated cholestasis have not fully been elucidated. Nei-
ther the excretion of potential substrates including a broad
range of clinically relevant drugs nor the expression of the
exclusively digoxin transporting Oatp2 and the ‘‘liver spe-
cific’’ Oatp4 at both protein and mRNA level has been
studied in estrogen-related cholestasis yet.
To get further insights into the mechanisms by which
these basolateral organic anion transporters might be regu-
lated under the influence of estrogen, we have character-
ized the expression of Oatp2 and Oatp4 in comparison to
Oatp1 and Ntcp. In addition, nuclear binding activities of
known transactivators of these transporter genes such as
hepatocyte nuclear factor 1 (HNF1), CAAT enhancer bind-
ing protein (C/EBP), retinoid X receptor:retinoic acid
receptor (RXR:RAR) and retinoid X receptor:pregnane X
receptor (RXR:PXR) were determined in EE induced
cholestasis.
2. Materials and methods
2.1. Animal models
Male Sprague–Dawley rats (250–300 g) were obtained
from the animal facility of Aachen University of Technol-
ogy. Cholestasis was induced in each animal by continuous
daily subcutaneous injections of sterile 17a-ethinylestradiol
dissolved in 1,2-propanediol (5 mg/ml, Sigma) for up to 5
days as previously described [3,11]. Control animals were
daily injected with 1,2-propanediol alone. Animals were
maintained on a 12-h light and 12-h night cycle with free
access to standard chow and water. Livers were harvested
either 0.5, 1, 3 or 5 days after injection, immediately frozen
in liquid nitrogen for protein and RNA-analysis or freshly
used for isolation of nuclear extracts. All study protocols
were approved by the Federal Government’s Animal Care
Committee.
2.2. Northern blot analysis
RNA was isolated from whole liver by Ultraspeck
phenol chloroform extraction procedure (Biotecx Laborato-
ries Inc., Houston, TX) according to the instruction manual,
quantified spectrophotometrically at 260 nm and stored at
 70 jC. Total RNA (10–20 Ag) was denatured, electro-
phoresed on a 1% agarose/formaldehyde gel, transferred to a
nylon membrane (Nytran 0.2; Schleicher&Schu¨ll, Dassel,
Germany) by overnight capillary blotting and UV-cross-
linked (UV Stratalinker 1800, Stratagene, La Jolla, CA).
Ethidium bromide staining of 18S and 28S bands was used
to ensure equal loading for each sample. The membranes
were prehybridized for 30 min at 60 jC in ExpressHybk
solution (Clontech, Palo Alto, CA). After replacement with
fresh ExpressHyb solution, hybridization was performed at
60 jC for 1 h after addition of specific rat complementary
DNA (cDNA) probes labeled with [32P]dCTP (specific
activity 108 cpm/Ag) by a random primed method (High
Primek, Boehringer Mannheim, Mannheim, Germany).
Blots were washed twice with 2 SSC/0.05% SDS for
10 min at room temperature, followed by 2 SSC/1% SDS
for 20 min at 50 jC. Specific mRNA levels were detected
after exposure of membranes to a Phosphoimager screen
(Biorad, Munich, Germany) and quantified using a Personal
Molecular Imager FX (Biorad). Specific and constitutively
expressed probes used were as previously described
[19,24,25]: Ntcp cDNA (0.9 kb EcoRI fragment), Oatp1
cDNA (0.7 kb PflMI fragment), Oatp2 cDNA (3.7 kb
EcoRI/BSSHII fragment), Oatp4 cDNA (0.4 kb NcoI/Hin-
dIII fragment), ecto-ATPase cDNA (1.3 kb XbaI/PstI frag-
ment) and GAPDH cDNA (1.3 kb PstI fragment).
2.3. Western blot analysis
Preparation of liver microsomes and analysis of protein
mass of various polypeptides were performed as previously
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described [25,26]. Protein concentrations were determined
according to Bradford [27]. After determination of the linear
range (25–200 Ag), similar amounts of protein (75 Ag) were
separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis [28], transferred to polyvinylidene fluoride
blotting membranes (Biotrace, Gelman Sciences, Roßdorf,
Germany), and probed to either anti-Ntcp fusion protein
antiserum [29], anti-Oatp1 fusion protein antiserum [30],
anti-Oatp2 peptide antiserum [17], anti-Oatp4 peptide anti-
serum [23] and monoclonal anti-Na+/K+-ATPase a-1 anti-
body (Upstate Biotechnology, Lake Placid, NY). Immune
complexes were detected using horseradish peroxidase-con-
jugated donkey anti-rabbit IgG F(abV)2 fragments according
to the ECLkWestern blotting kit (Amersham, Little Chal-
font, England). Immunoreactive bands obtained by auto-
radiography were quantified by laser densitometry (Fluor S
MultiImager, Quantity Onek software, Biorad).
2.4. Electrophoretic mobility shift analysis
Preparation of nuclear extracts and electrophoretic mobi-
lity shift assays were performed as previously described
[31–33]. Protein concentrations were determined according
to Bradford [27]. Nuclear extracts (5–10 Ag protein) were
incubated on ice for 30 min with a specific [32P]end-labeled
oligonucleotide probe (2 104 cpm, see Table 1) in a 20-Al
reaction containing 8-Al water, 4-Al 5 binding buffer (25
mM HEPES pH 7.6, 50 mM KCl, 0.5 mM DTT, 5 mM
MgCl2, 0.5 mM EDTA, 10% glycerol) and 2-Ag poly(dI–
dC)–poly(dI–dC) (Pharmacia Biotech, Freiburg, Germany).
For competition assays, 100-fold molar excess of specific
unlabeled oligonucleotides were added with the labeled
oligonucleotide to the binding reaction. Separation of pro-
tein–DNA complexes from the unbound labeled probe was
performed by electrophoresis through a nondenaturing 6%
polyacrylamide gel. Dried gels were exposed both to auto-
radiography and Phosphoimager screens, the latter used for
quantification as described above for Northern blot analysis.
2.5. Statistical analysis
Statistical significance (P < 0.05) between controls and
EE-treated animals was determined by multivariate ANOVA
and posttesting. Data represent the meanF S.D. of at least
four animals per group.
3. Results
3.1. Effects of EE on steady-state mRNA levels
To determine whether mRNA expression of hepatocel-
lular organic anion transporters was altered during the
cholestatic response to EE injection, we quantified steady-
state mRNA levels of transport proteins exclusively local-
ized to the basolateral plasma membrane of hepatocytes
(Ntcp, Oatp1, -2 and -4) by Northern blot analysis (Fig. 1).
The most extensive down-regulation was observed at the
basolateral plasma membrane for Oatp2 mRNA, which
declined on average to 8F 2% of control levels 5 days after
EE treatment (P < 0.05, n = 4). Similar to Oatp2, Ntcp and
Oatp1 decreased, but to a lesser extent as shown by an
average reduction of specific mRNA to 33F 4% and
43F 6% (P < 0.05, n = 4), respectively. In contrast to all
other basolateral organic anion transporters, Oatp4 mRNA
remained largely unchanged during the whole time course
with a slight but significant reduction to 77F 6% (P < 0.05,
n = 4) after 3 days (Fig. 2). Densitometric data shown in Fig.
2 demonstrate that mRNA reduction of Ntcp and Oatp2
followed a rapid time course with a 70% reduction within
the first 12 h, while Oatp1 declined slowly to a 5-day
minimum after EE treatment. In contrast to reductions in
mRNA levels of organic anion transporters, mRNA levels of
the housekeeping gene GAPDH remained unchanged at any
time point after EE treatment (Fig. 1).
3.2. Protein expression after EE injection
To study whether alterations in steady-state mRNA levels
resulted in reduced protein expression of hepatocellular
organic anion transporters, protein levels of various trans-
porters including the basolateral Oatp1, -2 and -4 were
Table 1
DNA sequences of oligonucleotides used for electrophoretic mobility shift
analyses







Fig. 1. Effect of EE on steady-state mRNA levels of organic anion
transporters. Rats (n= 4) were treated either with EE or solvent alone
(sham-controls) for up to 5 days. Total RNA was isolated from livers as
described, blotted onto nylon membrane and hybridized to specific cDNA
probes as described in Materials and methods. Blots were then stripped and
rehybridized with a GAPDH cDNA probe. Representative autoradiographs
are shown for each treatment period.
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quantified by Western blotting (Fig. 3). Protein levels of the
basolateral Ntcp was significantly reduced between 0.5 and
5 days (17F 4% at day 3 and 33F 2% at day 5, respec-
tively, P < 0.05, n = 4) in parallel to mRNA levels (Fig. 4).
In contrast, Oatp1 and -2 protein levels remained statisti-
cally unaffected for the first 24 h of treatment and thereafter
declined to a lesser extent compared to Ntcp (59F 10% and
63F 7%, respectively, at day 5, P < 0.05, n= 4; Figs. 3 and
4). In contrast to largely unchanged mRNA levels, Oatp4
protein slightly but significantly declined between 3 and 5
days of EE treatment to 72F 11% (P < 0.05, n = 4) at day 5
as shown in Fig. 3. The decrease in organic anion trans-
porter protein mass appeared to be specific since the baso-
lateral inorganic ion exchanger Na+, K+-ATPase remained
unchanged (Fig. 3).
3.3. Effects of EE on binding activity of transcription fac-
tors
To further elucidate the mechanisms of EE-induced
differential down-regulation of basolateral organic anion
transporters at the mRNA level, we performed electropho-
retic mobility shift assays with nuclear extracts isolated
from animals at two different time points (24 and 72 h)
after EE application. Oligonucleotides representing consen-
sus binding sites for previously identified nuclear trans-
activators of the Ntcp gene [34,35] including HNF1, C/EBP
and RXR:RAR as well as RXR:PXR, a transactivator of rat
Oatp2, were used for EMSA (Fig. 5). Since estrogen
receptors (ER) not only bind to estrogen response elements
(ERE) but also affect transcription at activating protein-1
(AP-1) sites [36,37], oligonucleotides with the binding site
for ER in the rat Ntcp promoter (nt  184/ 165) and a
consensus binding sequence for AP-1 were included in this
study. Analysis of nuclear extracts isolated 24 h after EE
showed a decrease in binding activity of the known Ntcp
transactivator C/EBP to 46F 16% (P < 0.05, n = 4), with a
further decline to 35F 13% after 3 days (P < 0.05, Figs. 5
Fig. 2. Densitometric analysis of basolateral organic anion transporter mRNA in EE-treated rats. Autoradiographs were quantified by phosphoimaging and data
were expressed as percentage of sham-controls (n= 4). Data are given as meanF S.D. *P < 0.05 as compared to sham-controls.
Fig. 3. Effect of EE on organic anion transporter protein levels. Membrane
fractions were isolated from the same animals described in Fig. 1, subjected
to SDS-PAGE (75 Ag protein/lane), and subsequently blotted onto
polyvinylidene fluoride blotting membranes as described in Materials and
methods. Representative immunoblots are shown for each treatment period.
Molecular weight (MW) markers are given in kilodaltons.
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and 6). In contrast, HNF1 binding activity remained
unchanged at day 1 and declined to 61F 21% (P < 0.05,
n = 4) at day 3. Binding to an RXR:RAR responsive element
was largely unaffected by EE treatment at day 1 and even
increased at day 3 as shown in Fig. 6. In contrast to
RXR:RAR, nuclear binding activity of RXR:PXR, a tran-
scription factor that induces Oatp2 expression, was initially
unchanged (103F 10%) but thereafter decreased to
40F 4% compared to controls (P < 0.05, n = 4). AP-1 bind-
ing activity appeared to be increased at both 1 and 3 days
after EE treatment to 217F 40% and 258F 64%, respec-
tively (P < 0.05, n = 4). Interestingly, nuclear protein bind-
ing to the ERE of the Ntcp gene promoter was largely
unchanged by EE treatment with a decrease to 55F 21%,
which was statistically not significant (P>0.05, n = 4) (Figs.
5 and 6).
Fig. 4. Densitometric analysis of transporter protein levels in EE-treated rats. Autoradiographs were quantified by laser densitometry, and data were expressed
as percentage of sham-controls (n= 4). Data are given as meanF S.D. *P< 0.05 as compared to sham-controls.
Fig. 5. Effect of EE on DNA binding activity of various transcription
factors. Hepatic nuclear extracts were prepared from sham-controls and EE
treated rats (n= 4) 24 and 72 h after either treatment. Nuclear extracts (5–
10 Ag protein) were incubated with radiolabeled oligonucleotides, electro-
phoresed through a 6% nondenaturing polyacrylamide gel (EMSA) and
autoradiographed. Representative autoradiographs of hepatic DNA binding
proteins from two independent samples are shown. Differences in band
intensity between control samples isolated at day 1 or day 3 are explained
by separate gel analysis and exposure of the X-ray film. SC: specific
competition; NSC: nonspecific competition.
Fig. 6. Densitometric analysis of DNA binding activity. Autoradiographs
obtained after EMSA were quantified by phosphoimaging and data were
expressed as percentage of sham-controls (n= 4). Data are given as
meanF S.D. *P < 0.05 as compared to sham-controls.
A. Geier et al. / Biochimica et Biophysica Acta 1609 (2003) 87–94 91
4. Discussion
Intrahepatic cholestasis can be induced by ethinylestra-
diol (EE) with a reduction in overall bile flow to about 60%
and an increase of bile acids in serum but not within
hepatocytes [5,3,38]. Functional studies show both dimin-
ished sinusoidal taurocholate (Tc)-uptake as well as canal-
icular Tc-secretion within 5 days of EE application [5].
Impaired Tc-uptake is primarily caused by diminished
sodium-dependent Tc-transport, whereas sodium-independ-
ent Tc-uptake is almost unaffected [3]. In parallel to these
effects caused by exogenous estrogens, female gender and
pregnancy are also associated with reduced Tc-uptake in
hepatocytes [39–41]. Previous studies revealed that changes
in transport activity are associated with a decrease in
expression of Ntcp and Oatp1 at the basolateral plasma
membrane and Mrp2 at the canalicular membrane, whereas
Bsep is relatively well preserved [3,6,11].
In the present study, we have extended our knowledge of
transporter expression to Oatp2 and Oatp4 as two recently
identified members of the Oatp family to determine why
sodium-independent transport remains unchanged in EE
cholestasis despite down-regulation of Oatp1 expression
[3]. In addition, we have analyzed various transcription
factors in this model of cholestasis to delineate the molec-
ular mechanisms by which down-regulation of organic
anion transporters might occur.
In regard to mRNA expression, Oatp2 showed a similar
pattern as Ntcp with a rapid down-regulation within 12 h
after the first EE injection with similar levels even at later
time points (Figs. 1 and 2). In agreement with previous data,
Oatp1 mRNA also declined, but at a less pronounced rate,
probably due to strain-specific differences [3]. At the protein
level Oatp2 declined at a much slower rate than Ntcp
(33F 2%) with a final reduction in protein levels to
63F 7% of controls (Figs. 3 and 4). Similar to Oatp1 and
Oatp2, Oatp4 protein declined to the same extent although
its mRNA was largely unaffected in contrast to the other
basolateral organic anion transporters (Figs. 1–4). These
data suggest that Oatp4 is mainly regulated by posttranscrip-
tional mechanisms as previously shown in a model of toxic
liver injury [33]. The modest changes of all Oatps by
approximately 30% to 40% reduction in protein expression
may explain the unaffected overall sodium-independent Tc-
uptake due to their partially overlapping substrate specific-
ity.
Down-regulation of Ntcp protein and mRNA levels after
EE treatment is in accordance with previous studies in EE-
associated cholestasis [3] and in female rats compared to
male controls [39]. In the latter study, reduced mRNA
expression occurs by diminished transcriptional activity of
the Ntcp gene under the influence of estrogen as shown by
nuclear run off assays [39]. In regard to basolateral organic
anion transporters, gene regulation has only been further
elucidated for Ntcp after cloning its promoter and identi-
fication of transactivators driving its basal expression [31].
In endotoxin-induced cholestasis and toxic liver injury,
reduced gene transcription was due to diminished binding
activity of Ntcp transactivators such as HNF1, C/EBP and a
heterodimer of RXR and RAR [33,34]. In particular,
decreased binding activity of HNF1a and C/EBPa has been
crucial in both toxic hepatitis and endotoxin-induced cho-
lestasis, whereas reduced RXRa:RARa DNA interaction
was confined to endotoxin-induced cholestasis [34,33].
In estrogen-induced cholestasis, nuclear binding activity
of the Ntcp transactivator RXR:RAR remained unchanged,
whereas both HNF1 and C/EBP were significantly reduced
after 1 and 3 days of treatment (Figs. 5 and 6). Transcrip-
tional regulation of target genes by estrogens occurs by
binding of the ligand to the ER, which is located in the
cytoplasm and translocated to the nucleus [42]. In the
nucleus the activated ER mediates gene regulation either
directly by binding to estrogen response elements (ERE) in
target genes (‘‘classical pathway’’) or indirectly by activa-
tion or suppression of gene transcription at alternative DNA
elements (‘‘nonclassical’’ pathway) [37]. DNA sequences
for binding of the transcription factor AP-1 represent such
alternative binding sites, by which ER may affect transcrip-
tional activity after protein–protein interaction with AP-1
[43,36]. To our knowledge, the mechanisms by which
estrogens finally affect Ntcp gene transcription are presently
unknown. Sequence analysis revealed a potential ERE in the
Ntcp gene at nt  184/ 165, which, however, did not
show any changes in binding activity when assayed by
EMSA (Fig. 5). In addition, multiple potential AP-1 sites are
present within the Ntcp gene, even within the minimal
promoter region [34]. Since a direct binding of ERE on
the Ntcp promoter sequence could not be demonstrated by
EMSA, we determined AP-1 binding activity after EE
injection, which was increased at both 1 and 3 days after
treatment (Figs. 5 and 6). However, direct interaction of
ERE and AP-1 has been difficult to demonstrate since these
interactions are not strong enough to be detected by a
supershift of AP-1 bound to ER by EMSA or coimmuno-
precipitation studies [43]. Alternatively to an indirect regu-
lation of Ntcp by EE via AP-1/ERE, EE may affect
expression of Ntcp by modulation of its transactivators such
as HNF1 and C/EBPa. HNF1 contains putative ERE bind-
ing sites in its promoter region, whereas C/EBPa does not
exhibit these consensus sequences in its 5Vflanking region
by TRANSFAC analysis. Which mechanisms finally regu-
late Ntcp gene expression in EE cholestasis needs to be
determined in more details in future studies.
Transcriptional regulation of Oatps has not been studied
in great details due to the lack of cloning its various genes
except for the very recent characterization of the Oatp2
5Vflanking region [44]. Studies in PXR / mice sug-
gested that the PXR, which acts as a physiological sensor
for toxic bile acids including lithocholic acid, controls the
inverse transcriptional regulation of cholesterol 7a-hydrox-
ylase (Cyp7a1) as the key enzyme of bile acid synthesis
and Oatp2 [45]. These in vivo data are confirmed by the
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identification of several consensus sequences of PXR in
the Oatp2 gene promoter, which are transactivated by PXR
ligands in cotransfection studies [44]. EE has also been
shown to act as a PXR ligand in addition to several other
natural steroids and moderately activates PXR-mediated
reporter gene expression [46]. Thus, PXR binding activity
was assessed in nuclear extracts from EE-treated animals
(Fig. 5). In addition, the Oatp2 5Vflanking region contains
several putative binding sites for HNF1 [44]. However, the
discrepancy between rapid down-regulation of Oatp2
mRNA (Figs. 1 and 2) and sustained binding activity of
both PXR and HNF1 (Figs. 5 and 6) 24 h after EE
injection suggests that other factors are even more impor-
tant in regard to Oatp2 gene expression at this early time
point of EE-induced cholestasis than HNF1 and PXR.
Later, decreased binding activity of both HNF1 and PXR
may contribute to sustained down-regulation of Oatp2
gene expression (Figs. 5 and 6).
In summary, estrogen-induced cholestasis results in mod-
erate down-regulation of all known basolateral organic
anion transporting polypeptides including Oatp1, Oatp2
and Oatp4 in addition to the more pronounced decline in
Ntcp expression. The largely maintained expression of the
Oatps may provide an explanation at the molecular level for
the unaltered sodium-independent transport of bile acids in
this model of intrahepatic cholestasis. In case of Ntcp,
decreased gene expression seems to be mediated by
decreased nuclear binding activity of transactivators such
as HNF1 and C/EBP. In regard to Oatp2, PXR and HNF1
may play a role in sustained down-regulation of gene
expression during the later period of EE-induced choles-
tasis.
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